Lead Sponsor

Women's College Hospital

Collaborators

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•1. Age ≥ 18 years old
•2. Kidney, liver, heart, or lung transplant at least two years ago
•3. History of at least one prior histologically-confirmed keratinocyte carcinoma or squamous cell carcinoma in situ
•4. Currently immunosuppressed with a calcineurin inhibitor-based regimen (cyclosporine or tacrolimus)
•5. Able to attend follow-up visits
•6. Able to speak and understand English (only for cognitive substudy)

•1. Use of mTOR inhibitor (sirolimus, everolimus) within the past 12 weeks
•2. Biopsy-confirmed acute rejection episode within the past 12 weeks
•3. Active liver disease (elevated AST or ALT \>3 times normal)
•4. Severe renal failure (estimated glomerular filtration rate \<20 mL/min/1.73 m2)
•5. Current carbamazepine or primidone use
•6. Pregnancy and lactation
•7. Gorlin syndrome or other genetic skin cancer syndrome
•8. Solid organ or hematologic malignancy, invasive Stage II melanoma, Merkel cell carcinoma, or metastatic skin cancer within the past five years, or invasive Stage I melanoma within the past two years
•9. Untreated localized skin cancer (invasive squamous cell carcinoma, basal cell carcinoma, or keratoacanthoma) at baseline (the patient can enrol after skin cancer treatment)
•10. Use of nicotinamide or niacin (250 mg or more daily) within the past 12 weeks
•11. Use of field therapy for actinic keratoses within the past 12 weeks
•12. Initiation of systemic chemoprevention within the past 12 weeks

Related studies

NCT07410676 · Cancer, Sarcoma, and more

NCT04099290 · Head and Neck Neoplasm, Carcinoma, Squamous Cell

NCT04844528 · Chronic Lymphocytic Leukemia, Non-melanoma Skin Cancer (NMSC)

NCT06912087 · Head and Neck Neoplasms, Carcinoma, Squamous Cell, and more

NCT04429542 · Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, and more

Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial